Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the chronic obstructive pulmonary disease (COPD) population in China will experience growth, due to an expanding diagnosed and drug-treated population. According to the new Emerging Markets report entitled COPD in China, the diagnosed and drug-treated populations will increase at annual rates of 1.6 percent and 2.2 percent, respectively, over the next five years. The greatest growth in the prevalent population will be seen in the urban setting among patients aged 60-70 years and those aged 80 years and older. Additional drivers of market growth include improvements in health insurance and in the socioeconomic status of patients.

The report also finds that significant factors are currently constraining the COPD market, including a lack of disease awareness, patients' limited access to care (particularly in the rural setting), the high cost of drugs, and reimbursement restrictions placed on certain agents. Additionally, inexperienced Chinese physicians who are unaware of or don't have access to spirometry (the most common of the Pulmonary Function Tests which measures lung function) confuse COPD with asthma, thus providing less optimal disease management. Chinese physicians also struggle with low compliance rates among their patients, further constraining optimal drug sales.

"China's COPD market presents a potentially lucrative opportunity for multinational corporations," said Regina Cebula Jammen, analyst at Decision Resources. "By establishing effective COPD awareness programs in collaboration with China's Global Alliance Against Chronic Respiratory Diseases, multinational corporations have the opportunity to tap into a COPD prevalent population that is significantly underdiagnosed and undertreated."

About Emerging Markets -- China

Emerging Markets -- China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

  -- More accurately assess their commercial opportunity for Western brands      in key pharmaceutical markets of China -- Beijing, Shanghai,      Guangzhou -- and in the high-growth second-tier markets of Tianjin,      Wuhan, Nanjing, Hangzhou, and Jinan.   -- Understand the physician treatment patterns and drivers of choice in      key first- and second-tier cities based on primary research.   -- Gain a clear perspective of the Chinese 5-year market forecast at the      drug level, broken out by urban and rural areas, and by sales from      multinational and Chinese-based companies.    About Decision Resources  

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia

View Now